Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | MRK | Common Stock | Options Exercise | $87.6K | +1.17K | +46.81% | $75.04 | 3.66K | Feb 10, 2021 | Direct | |
transaction | MRK | Common Stock | Tax liability | -$35K | -467 | -12.76% | $75.04 | 3.19K | Feb 10, 2021 | Direct | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | MRK | Restricted Stock Unit | Options Exercise | $0 | -1.17K | -33.32% | $0.00 | 2.34K | Feb 10, 2021 | Common Stock | 1.17K | Direct | F2, F3, F4 |
Id | Content |
---|---|
F1 | Holdings include shares acquired in dividend reinvestment transactions; reflects holdings as of February 10, 2021. |
F2 | Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. |
F3 | These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 2/10/2021, 2/10/2022 and 2/10/2023. |
F4 | Holdings were adjusted to 2,407 as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. |